EUVIMEDEUVIMED entdecken
Crossref

L26/P-012 Selective Clinical Utility of Microfluidics Sperm Sorting Across IVF Indications: A Retrospective Comparative Study

K. Parmar, S. Venkatesh, K. Chaitanya, D.R. Gedela

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von K. Parmar und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Does microfluidics sperm sorting improve IVF outcomes compared with density gradient centrifugationacross different, indication-based clinical settings? Summary answer Microfluidics sperm sorting showed benefit when selectively used, particularly in high sperm DNAfragmentation, advanced paternal age, and previous IVF failure, but not as routine technique. What is known already Elevated sperm DNA fragmentation (DFI) adversely affects embryo development, implantation, miscarriage,and live birth outcomes. Microfluidics sperm sorting (MFSS) is a centrifugation-free technique that mimicsphysiological sperm selection and enriches motile sperm with lower DNA damage. While MFSS has primarilybeen used for raised DFI, its application has expanded to routine sperm preparation, advanced paternal age,and repeated IVF failure. However, evidence supporting its universal use across all IVF indications remainslimited. Study design, size, duration This retrospective cohort study included 2,957 IVF/ICSI cycles performed between 2019 and 2024. Cycleswere stratified into five predefined groups: donor oocyte cycles with normal DFI (n = 740), self-oocyte cycleswith normal DFI (n = 1,174), high DFI cycles (n = 426), advanced paternal age (>40 years) cycles (n = 91), andprevious failed IVF cycles (n = 164). Outcomes following MFSS were compared with density gradientcentrifugation (DDG) within each group. Participants/materials, setting, methods Raised sperm DNA fragmentation was defined as ≥ 25% by sperm chromatin structure assay (SCSA), andpaternal age >40 years as advanced. All cycles involved frozen embryo transfer of two good-grade blastocysts,standardising embryo quality and transfer strategy. Outcomes assessed included cycle cancellation, blastocystformation, clinical pregnancy, implantation, miscarriage, multiple pregnancy, and live birth rates. Group-wiseanalyses were performed to minimise confounding by indication. Main results and the role of chance In donor oocyte cycles with normal DNA fragmentation, MFSS and density gradient centrifugation yieldedcomparable clinical pregnancy (61.5% vs 60.6%) and live birth rates (54.4% vs 53.9%), with a numericallylower miscarriage rate following MFSS (5.6% vs 12.8%), suggesting no clear advantage for routine use.In self-oocyte cycles with normal DNA fragmentation, MFSS was associated with higher clinical pregnancy(65.7% vs 61.5%) and live birth rates (52.7% vs 43.0%), with lower miscarriage rates (12.9% vs 18.5%).However, these findings did not support universal benefit across all normal DNA fragmentation cycles.In high DNA fragmentation cycles, MFSS was associated with lower cycle cancellation (4.6% vs 19.6%), higherimplantation (45.4% vs 23.4%), higher live birth rates (46.9% vs 26.8%), and reduced miscarriage.Among advanced paternal age cycles, MFSS showed higher clinical pregnancy (70.0% vs 46.6%) and live birthrates (58.3% vs 30.0%). In previous failed IVF cycles, MFSS was associated with higher clinical pregnancy(34.5% vs 12.8%) and live birth rates (28.4% vs 10.0%). Given the retrospective design, findings aredescriptive and associative. Limitations, reasons for caution The retrospective design, unequal subgroup sizes, clinician-driven selection of sperm preparation technique,and absence of post-processing molecular sperm assessment introduce potential residual confounding andlimit causal inference. Wider implications of the findings MFSS demonstrates clinical benefit when applied selectively, particularly in cycles with elevated sperm DNAfragmentation, advanced paternal age, and repeated IVF failure. Routine use in cycles with normal DNAfragmentation is not supported, reinforcing indication-based application consistent with ESHRE add-onguidance. Trial registration number No

Zitieren

APA

Parmar, K., Venkatesh, S., Chaitanya, K., & Gedela, D. (2026). L26/P-012 Selective Clinical Utility of Microfluidics Sperm Sorting Across IVF Indications: A Retrospective Comparative Study. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.348

Vancouver

Parmar K, Venkatesh S, Chaitanya K, Gedela D. L26/P-012 Selective Clinical Utility of Microfluidics Sperm Sorting Across IVF Indications: A Retrospective Comparative Study. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.348

BibTeX
@article{Parmar2026,
  author = {Parmar, K. and Venkatesh, S. and Chaitanya, K. and Gedela, D.R.},
  title = {L26/P-012 Selective Clinical Utility of Microfluidics Sperm Sorting Across IVF Indications: A Retrospective Comparative Study},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.348}
}
Kostenlos starten →